Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002069340 | SCV002401348 | benign | not provided | 2022-09-30 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV002246238 | SCV002518285 | uncertain significance | not specified | 2022-05-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002570514 | SCV003568272 | uncertain significance | Inborn genetic diseases | 2021-08-02 | criteria provided, single submitter | clinical testing | The c.2699C>G (p.T900R) alteration is located in exon 23 (coding exon 23) of the FBXO11 gene. This alteration results from a C to G substitution at nucleotide position 2699, causing the threonine (T) at amino acid position 900 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Centre de Biologie Pathologie Génétique, |
RCV001252493 | SCV001428250 | likely pathogenic | Intellectual developmental disorder with dysmorphic facies and behavioral abnormalities | 2019-01-01 | no assertion criteria provided | clinical testing |